AMN Healthcare Posts Fair Q4 Results While Contract Labor Enters Expected Decline

Temporary staffing volume is beginning to decrease.

""
Securities In This Article
AMN Healthcare Services Inc
(AMN)

Narrow-moat AMN Healthcare AMN posted relatively mild fourth-quarter results as temporary staffing volume begins to decline behind the scenes. In 2022, the healthcare staffing industry saw bill rates fall from a pandemic peak that was unmaintainable for healthcare facilities. In 2023, we expect a decline in volume to catch up with the drop in bill rates as hospitals streamline costs. Though the quarter was slightly less negative than we expected, management expects headwinds that are consistent with what we’ve modeled, so we maintain our fair value estimate of $102 per share.

In our previous note this month, we explained that temporary labor demand can decline during economic slowdowns as hospitals increase permanent staff to tame high temporary labor costs. This appears to be playing out, as facility operators like HCA and Tenet Healthcare were able to materially reduce temporary labor costs during the fourth quarter. Although AMN posted flat results in its nurse and allied solutions segment this quarter, we will likely see the full effect of the temporary labor reduction next quarter, and likely more, since further reductions are expected by facility operators. We expect to see declines in the locum tenens and vendor management system businesses, as well.

On the other hand, the current economic slowdown differs from those prior due to the serious healthcare labor shortage. We think this puts a higher floor on how far facilities can lower their contract labor costs, since there just aren’t enough workers to go around. In addition, AMN’s high-margin language services business has posted 23% growth year over year, partially offsetting declines in staffing. This is consistent with what we’ve heard from facility operators, which are looking to auxiliary technology to assist strained employees with handling a normal patient capacity.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Debbie S. Wang

Senior Equity Analyst
More from Author

Debbie S. Wang is a senior equity analyst, AM Healthcare, for Morningstar*. She covers the medical-device, diagnostics, and animal health industries. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.

Prior to joining Morningstar 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald's, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.

Wang holds a bachelor’s degree in anthropology from Colgate University. She also holds a a master’s degree in business administration from the University of Chicago Booth School of Business.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center